GlassScriptPhysician profile
Richard A Jimenez
NPI 1366484040
$155,308.47
in general payments reported to CMS, 2019-2025
38 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $25K · 2021: $6,725 · 2022: $14K · 2023: $9,732 · 2024: $13K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $11K · Food and Beverage: $8,364 · Travel and Lodging: $2,346 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,883.75 |
| Consulting Fee | $10,977.50 |
| Food and Beverage | $8,364.47 |
| Travel and Lodging | $2,346.46 |
| Education | $109.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44,786.18 | 2019-2025 | Otezla, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $28,597.72 | 2019-2025 | |
| Celgene Corporation | $18,146.91 | 2019 | |
| Abbvie INC. | $14,908.30 | 2019-2025 | |
| Horizon Therapeutics Plc | $13,198.83 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $9,515.64 | 2019-2025 | Tremfya, Stelara, Remicade |
| Mallinckrodt Enterprises LLC | $9,436.81 | 2019 | |
| Kyowa Kirin, INC. | $6,628.63 | 2023-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $2,772.50 | 2021-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $1,737.81 | 2020 | |
| Ucb, INC. | $883.67 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $600.45 | 2019-2024 | Orencia |
| Glaxosmithkline, LLC. | $597.43 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $582.83 | 2019-2025 | Taltz, Zepbound |
| Sobi, INC | $429.77 | 2019-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.